Hepatitis B virus (HBV) remains the major health concern with 260 million people infected globally and 680,000 deaths by cirrhosis and liver cancer annually. HBV capsid assembly modulation has emerged as a promising therapeutic approach for the cure of HBV infection. The two major classes of small-molecule capsid modulators are HAPs (heteroaryldihydropyrimidines) and SBAs (Sulfamoylbenzamides). SBAs are known as capsid activators inhibiting viral replication by achieving the capsid assembly before polymerase encapsulation. Herein report a novel series of HBV capsid inhibitors based on the NVR 3-778, a class of SBAs. The compounds described exhibit improved pharmacological activity and we have explained this observation on the basis of molecular docking studies. .<br/>

Design, synthesis, and biological evaluation of sulfamaoylbenzamide derivatives as hepatitis B virus capsid inhibitors

2019 Fall National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.